%0 Journal Article
%T Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.
%A Argüelles-Arias F
%A Rodriguez González FJ
%A González Antuña J
%A Castro Laria L
%A Gutiérrez Martinez F
%A Alcaín Martinez G
%A Maldonado Pérez B
%A Camargo Camero R
%A Martos Van Dussen JV
%A Fernández Castañer A
%A Valdés Delgado T
%J Inflamm Bowel Dis
%V 0
%N 0
%D 2024 Jul 31
%M 39082955
%F 7.29
%R 10.1093/ibd/izae152
%X <B>BACKGROUND: </B>Ustekinumab (UST) is commonly used to treat Crohn's disease and ulcerative colitis. However, some patients may experience diminishing response or require increased dosage. Intravenous (IV) UST maintenance is explored as a solution.<BR><B>OBJECTIVE: </B>We sought to evaluate IV UST maintenance effectiveness and safety in inflammatory bowel disease patients with partial or lost subcutaneous UST response.<BR><B>METHODS: </B>This was a multicenter retrospective study of inflammatory bowel disease patients on IV UST maintenance. Clinical response and remission at weeks 12 and 52, defined as Harvey-Bradshaw Index ≤4 for Crohn's disease or partial Mayo score ≤2 for ulcerative colitis. Objective markers reduction (fecal calprotectin, C-reactive protein), UST trough levels pre- and post-IV maintenance, and adverse events were assessed.<BR><B>RESULTS: </B>A total of 59 patients were included. Clinical remission at weeks 12 and 52 achieved by 47.5% and 64.3% respectively. 96.6% continued IV UST at follow-up. UST serum levels quadrupled. No adverse events reported.<BR><B>CONCLUSIONS: </B>IV UST maintenance effectively sustained remission in most patients at 52 weeks.<BR>When patients lose response to subcutaneous ustekinumab, strategies include reinduction, interval shortening, and less explored intravenous maintenance. Its high rescue rate and safety profile make it a valuable option for managing active inflammatory bowel disease.